We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Genetic Test Introduced for High-Risk Breast and Ovarian Cancer

By LabMedica International staff writers
Posted on 19 Jan 2016
Print article
Image: Histopathology of a left-ovarian mass showing a histologic picture similar to the breast carcinoma with sheets of high-grade tumor cells surrounded by a lymphoplasmacytic infiltrate. The patient had a BRAC2 gene mutation (Photo courtesy of NYU Langone School of Medicine).
Image: Histopathology of a left-ovarian mass showing a histologic picture similar to the breast carcinoma with sheets of high-grade tumor cells surrounded by a lymphoplasmacytic infiltrate. The patient had a BRAC2 gene mutation (Photo courtesy of NYU Langone School of Medicine).
A new 26-gene screening panel, myBRCA HiRisk is a comprehensive High-Risk Breast and Ovarian Cancer (HBOC) screening test specifically designed for high-risk populations has been introduced.

Earlier this year, myBRCA screening test for breast cancer 1/2 (BRCA1 and BRCA2) genes was introduced as the most out-of-pocket affordable breast and ovarian cancer screening test and myBRCA is currently offered in over 20 countries worldwide and received the European CE marking in 2015.

A recently published clinical study performed over 10 years at Massachusetts General, Stanford, and Beth Israel Deaconess hospitals supports the use of this test. The myBRCA HiRisk panel also includes genes known to be associated with Lynch syndrome, Cowden syndrome, Li-Fraumeni syndrome, Peutz-Jeghers syndrome and several other genetic syndromes, including Bloom syndrome, Fanconi Anemia, and Ataxia Telangiectasia.

The authors of the study concluded, “In a clinically representative cohort, multigene panel testing for HBOC risk assessment yielded findings likely to change clinical management for substantially more patients than does BRCA1/2 testing alone. This approach may improve clinical outcomes for high-risk individuals and their families and will improve cancer risk assessment and management recommendations for mutation-affected individuals across a broad spectrum of cancer predisposition genes.”

The Veritas Genetics' (Boston, MA, USA) high-risk panel test identifies germline mutations in 26 genes, including BRCA1 and BRCA2, which are associated with increased risk for developing breast and ovarian cancer as well as other associated cancers. myBRCA HiRisk also tests for structural rearrangements in BRCA1 and BRCA2. myBRCA costs USD 199, does not require insurance authorization and includes genetic counseling and can be performed using a saliva or blood sample.

Joseph V. Thakuria, MD, Genetics Chief Medical Officer at Veritas Genetics, said, “Screening for BRCA1 and BRCA2 mutations, as offered through the myBRCA test, should be the first step in a HBOC cancer prevention regimen for most people. The needs of patients in the high-risk category are served much better with the more comprehensive approach offered with our new myBRCA HiRisk multigene panel.”

Related Links:

Veritas Genetics


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.